Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

February 14, 2024

https://www.prnewswire.com/news-releases/ono-enters-into-a-drug-discovery-collaboration-and-option-agreement-with-shattuck-labs-to-generate-bifunctional-fusion-proteins-302061657.html

OSAKA, Japan, Feb. 14, 2024 /PRNewswire/ — Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. (Austin, Texas, USA; CEO: Taylor Schreiber; “Shattuck”) to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory diseases.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.